Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2007 1
2012 1
2013 3
2014 2
2015 3
2016 5
2018 2
2019 5
2020 6
2021 10
2022 6
2023 9
2024 6
2025 5

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

57 results

Results by year

Filters applied: . Clear all
Page 1
Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA-09): a randomised, open-label, phase 3 trial.
Herrlinger U, Tzaridis T, Mack F, Steinbach JP, Schlegel U, Sabel M, Hau P, Kortmann RD, Krex D, Grauer O, Goldbrunner R, Schnell O, Bähr O, Uhl M, Seidel C, Tabatabai G, Kowalski T, Ringel F, Schmidt-Graf F, Suchorska B, Brehmer S, Weyerbrock A, Renovanz M, Bullinger L, Galldiks N, Vajkoczy P, Misch M, Vatter H, Stuplich M, Schäfer N, Kebir S, Weller J, Schaub C, Stummer W, Tonn JC, Simon M, Keil VC, Nelles M, Urbach H, Coenen M, Wick W, Weller M, Fimmers R, Schmid M, Hattingen E, Pietsch T, Coch C, Glas M; Neurooncology Working Group of the German Cancer Society. Herrlinger U, et al. Among authors: schaub c. Lancet. 2019 Feb 16;393(10172):678-688. doi: 10.1016/S0140-6736(18)31791-4. Epub 2019 Feb 14. Lancet. 2019. PMID: 30782343 Free article. Clinical Trial.
Current status of precision oncology in adult glioblastoma.
Weller J, Potthoff AL, Zeyen T, Schaub C, Duffy C, Schneider M, Herrlinger U. Weller J, et al. Among authors: schaub c. Mol Oncol. 2024 Dec;18(12):2927-2950. doi: 10.1002/1878-0261.13678. Epub 2024 Jun 20. Mol Oncol. 2024. PMID: 38899374 Free PMC article. Review.
L-RNA aptamer-based CXCL12 inhibition combined with radiotherapy in newly-diagnosed glioblastoma: dose escalation of the phase I/II GLORIA trial.
Giordano FA, Layer JP, Leonardelli S, Friker LL, Turiello R, Corvino D, Zeyen T, Schaub C, Müller W, Sperk E, Schmeel LC, Sahm K, Oster C, Kebir S, Hambsch P, Pietsch T, Bisdas S, Platten M, Glas M, Seidel C, Herrlinger U, Hölzel M. Giordano FA, et al. Among authors: schaub c. Nat Commun. 2024 May 28;15(1):4210. doi: 10.1038/s41467-024-48416-9. Nat Commun. 2024. PMID: 38806504 Free PMC article. Clinical Trial.
The ATLAS/NOA-29 study protocol: a phase III randomized controlled trial of anterior temporal lobectomy versus gross-total resection in newly-diagnosed temporal lobe glioblastoma.
Schneider M, Potthoff AL, Ahmadipour Y, Borger V, Clusmann H, Combs SE, Czabanka M, Dührsen L, Etminan N, Freiman TM, Gerlach R, Gessler F, Giordano FA, Gkika E, Goldbrunner R, Güresir E, Hamou H, Hau P, Ille S, Jägersberg M, Keric N, Khaleghi-Ghadiri M, König R, Konczalla J, Krenzlin H, Krieg S, McLean AL, Layer JP, Lehmberg J, Malinova V, Meyer B, Meyer HS, Miller D, Müller O, Musahl C, Pregler BEF, Rashidi A, Ringel F, Roder C, Rössler K, Rohde V, Sandalcioglu IE, Schäfer N, Schaub C, Schmidt NO, Schubert GA, Seidel C, Seliger C, Senft C, Shawarba J, Steinbach J, Stöcklein V, Stummer W, Sure U, Tabatabai G, Tatagiba M, Thon N, Timmer M, Wach J, Wagner A, Wirtz CR, Zeiler K, Zeyen T, Schuss P, Surges R, Fuhrmann C, Paech D, Schmid M, Borck Y, Pietsch T, Struck R, Radbruch A, Helmstaedter C, Németh R, Herrlinger U, Vatter H. Schneider M, et al. Among authors: schaub c. BMC Cancer. 2025 Feb 20;25(1):306. doi: 10.1186/s12885-025-13682-3. BMC Cancer. 2025. PMID: 39979825 Free PMC article.
Quantitative assessment of residual tumor is a strong and independent predictor of survival in methylated glioblastoma following radiochemotherapy with lomustine/temozolomide.
Zeyen T, Böhm L, Paech D, Schäfer N, Tzaridis T, Duffy C, Nitsch L, Schneider M, Potthoff AL, Schneider-Rothhaar JL, Steinbach JP, Hau P, Kowalski T, Seidel C, Krex D, Grauer O, Goldbrunner R, Zeiner PS, Tabatabai G, Galldiks N, Stummer W, Hattingen E, Glas M, Gkika E, Vatter H, Radbruch A, Herrlinger U, Weller J, Schaub C. Zeyen T, et al. Among authors: schaub c. Neuro Oncol. 2025 Feb 10;27(2):557-566. doi: 10.1093/neuonc/noae205. Neuro Oncol. 2025. PMID: 39351820
Transient MRI changes and neurological deterioration in glioblastoma upon SARS-CoV-2 infection.
Zeyen T, Friker LL, Paech D, Schaefer N, Weller J, Zschernack V, Layer JP, Schneider M, Potthoff AL, Bernhardt M, Sanders C, Kristiansen G, Hoelzel M, Gkika E, Radbruch A, Pietsch T, Herrlinger U, Schaub C. Zeyen T, et al. Among authors: schaub c. J Cancer Res Clin Oncol. 2024 Sep 28;150(9):437. doi: 10.1007/s00432-024-05963-4. J Cancer Res Clin Oncol. 2024. PMID: 39340558 Free PMC article.
Vemurafenib for leptomeningeal melanomatosis.
Schäfer N, Scheffler B, Stuplich M, Schaub C, Kebir S, Rehkämper C, Mack F, Niehusmann P, Simon M, Greschus S, Kuchelmeister K, Herrlinger U, Glas M. Schäfer N, et al. Among authors: schaub c. J Clin Oncol. 2013 Apr 10;31(11):e173-4. doi: 10.1200/JCO.2012.46.5773. Epub 2013 Mar 4. J Clin Oncol. 2013. PMID: 23460716 No abstract available.
Distress in Neuro-Oncology Patients and Its Implications for Communication.
Roos C, Weller J, Landwehr C, Sciermoch A, Duffy C, Kohlmann K, Schaub C, Tzaridis T, Schneider M, Schuss P, Herrlinger U, Schäfer N. Roos C, et al. Among authors: schaub c. J Adv Pract Oncol. 2023 May;14(4):292-299. doi: 10.6004/jadpro.2023.14.4.3. Epub 2023 May 1. J Adv Pract Oncol. 2023. PMID: 37313277 Free PMC article.
A novel serum extracellular vesicle protein signature to monitor glioblastoma tumor progression.
Tzaridis T, Weller J, Bachurski D, Shakeri F, Schaub C, Hau P, Buness A, Schlegel U, Steinbach JP, Seidel C, Goldbrunner R, Schäfer N, Wechsler-Reya RJ, Hallek M, Scheffler B, Glas M, Haeberle L, Herrlinger U, Coch C, Reiners KS, Hartmann G. Tzaridis T, et al. Among authors: schaub c. Int J Cancer. 2023 Jan 15;152(2):308-319. doi: 10.1002/ijc.34261. Epub 2022 Sep 17. Int J Cancer. 2023. PMID: 36054558
Regorafenib in advanced high-grade glioma: a retrospective bicentric analysis.
Tzaridis T, Gepfner-Tuma I, Hirsch S, Skardelly M, Bender B, Paulsen F, Schaub C, Weller J, Schäfer N, Herrlinger U, Tabatabai G. Tzaridis T, et al. Among authors: schaub c. Neuro Oncol. 2019 Jul 11;21(7):954-955. doi: 10.1093/neuonc/noz071. Neuro Oncol. 2019. PMID: 31089718 Free PMC article. No abstract available.
57 results